Table 3

Secondary endpoint achievement

Beclomethasone arm* (N=193)Placebo arm** (N=192)P value
Number of days with temperature 38°C or more, median (IQR) days
In total population0 (0–0)0 (0–0)0.5
In subpopulations stratified on the severity of the disease on admission
 Asymptomatic (n=13*, 12**)0 (0–0)0 (0–0)1.0
 Mild disease (n=122*, 123**)0 (0–0)0 (0–0)0.6
 Moderately disease (n=58*, 57**)0 (0–0)0 (0–1)0.8
In subpopulations stratified on the age of the patient
 Less than 60 years (n=114*, 113**)0 (0–0)0 (0–0)0.2
 60 years or more (n=79*, 78**)0 (0–0)0 (0–0)0.4
Time to self-reported clinical recovery, median (IQR) days
In total population5 (3–7)5 (3–8)0.5
In subpopulations stratified on the severity of the disease on admission
 Asymptomatic (n=13*, 12**)0 (0–0)0 (0–4)0.4
 Mild disease (n=122*, 123**)5 (3–8)5 (3–7)0.9
 Moderately disease (n=58*, 57**)5 (3–7)6 (4–9)0.05
In subpopulations stratified on the age of the patient
 Less than 60 years (n=114*, 113**)5 (3–6)5 (3–8)0.4
 60 years or more (n=79*, 78**)5 (3–10)5 (3–10)0.9
Short-term outcome by day 28† in the total population0.8
Complete recovery, n (%)150149
Partial recovery, n (%)2730
Death, n (%)
 Direct COVID-19 death01
 Indirect COVID-19 death10
  • *Beclomethasone arm, ** Placebo arm.

  • †Symptomatic patients at randomisation.